C-CDA35 Alarm Bio
small molecules, chemical damage, cell senescence
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CDA3
C-CDA3C-CDA3small molecules, chemical damage, cell senescence
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.6 %���� 310 0 obj > endobj 884 0 obj >/Filter/FlateDecode/ID[ ]/Index[310 597]/Info 309 0 R/Length 1741/Prev 15248786/Root 311 0 R/Size 907/Type/XRef/W[1 3 1]>>stream h�ė�o�eƿ�m�h��������N�RF���N�P��ZZ(�e��!+���%��e��(C$ *�� 0\Q���~���� -\�y��8_��;� �q���4V�n4na � ja�4���҇o�e�{��2iV Dt����w�i���` �� �9��y~H91!���K� t�N�@:؟�G�/Խ�0� �˚�&�ꏎ����a�%+?�-�B���S�+��R�|mv��� +2�B�A��V!���? q� ���L�(q۴�9��q����.��B �ni��5�z��&�o�'X�:�l��a p�͕���s+$�S��I ��WȃjjR�%�ˁ�m�fxr;2Og��}�pۥI��=8��=���Xo�J����`W��Me���T&gQ)y�����Gr�9�zEh�X�b]OJޑ ���a��tѹ��(,; … ��-��6����I$E�/ơ�"���?/���`jGZ�����u��Z��m�߯�y� � E�Ww]N�Lr��aIq ��Tur�*�Rfp�[ &��_���[���Z�S�~x���U{� �T;�ݖ3�O�Ujŝ�|���# �}Eg����?���6��ki^6�o�;?���^���+¶��e�}� ~?���� ��-bW M� �5������Ϭ��0��)(��(��(��(��(��(��(��(��(��(��(��(��(��(��+R,iv�3��W1��,���Sڢ��2]\��� �n�U.g{��iN]�Ms������/�;���U�ܾ %�_������Ė$��&�����a Y��=M��]\$1 �z����˨��� ��I{��ڮsi�C���L�P���Y�+�o��_O[&�l�8ڷ��?����ʠ�S��m32'd��Q� �E(Ѝ�-_����s��k��� �O���`I'$�ҫ9RA��V�%���uKȆ�=�;��8?��D� … �=�vUʱ�zn�HY-�9�6|�c���,>i���I���ۊ���FWk�pH ݺ��ޭjΟ��/o�F�g{�`�c[�����4�خRFp��8#��k� ��b��F7%��R�����C� H\HA���Aޤ�� �@�RE �@���k>6�/b����� ���~��� f����I\ ��'�|w�O�7[��#��� �8�\e� y�5�[�^Ŵ�ƣ��~�K���1oNe�R-D2�YJ����m��ꢝ�ڥ�u��`RA��+}:�~t덳\*G��d��s�q߰ ��R�ό.`�� ��)9�'��+�?���i:�z}Ͽ�G��?���)q�O����(������?� ����4u�s����i�G�����=A�R�G?����H�zv�@��g���Rc�u�?��Ν�}�HLq��?��x ��*A�S���y����>����AH@������ �F�s�p ��R�S� ��ߝ 2��� g�JQ�` �4�c��J … ��=M7��#@�����;� �� �U�-�3�U2H ;�s�)\ 2��f "m8O� ��G|��)�_��$��>a��'��TLRfe�>RFp�T��g��>k�{v�8R�H_�u��c� DE�I�Jዷ ;���r*@R� � �F�>��S�@�C�n~Pǹ�'>�K2F��쌱�x�ӏ� P��H�FK�X��s�c�R{�U��1����V@I �-����Ka�[�BH;�E�2q�z�T�En u$Ƨs#p �l���S�3�7���N��'�_N����m�E�I��s� �@8�\ �66���d�#/�7��?��YZW�6Sʆ�|ۏ����@�'�x1��ܐ��c���R}����� � P],r�)g6�'�=�� �o����z���M�l7G"I��w���z�w�+��uX� W�3�G�^ojDۂ��S�#9�,��l��y��3��>��V=[ ��M-�\[�7�"2B��qɯ ��x59c�~7��W� ��Z��mfd … 02-20T01:54:08+03:00 2019-02-20T01:53:37+03:00 2019-02-20T01:54:08+03:00 Google application/pdf uuid:b8ab6670-6bde-4452-9176-4ad92b3fe891 uuid:751a4622-0312-4dd0-85c4-c4bcaec909b9 Adobe Acrobat Pro DC 19.10.20069 endstream endobj 176 0 obj >stream hޜ��NA E���=)JCIEt�"�D������"�xM�=���X���Q�� iqTb��FY��I���D���I;3YIN���%)լN����P���J�g#N>
%PDF-1.7 %���� 1 0 obj >/Metadata 89 0 R/ViewerPreferences 90 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 16 0 R 19 0 R] /MediaBox[ 0 0 594.96 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�r�8}w�����T��S)����d�����ak ��=�e%�;߳?��ƅ��ʈ��:�(��h�O7�?�� F2�'��3aL�\&�$e�������$������z��y�����I���zq�L�����t6KN�ϒ?�|������w4�� ����(K��[i�}w|��I��'�����z���۟QV$/��QtK��z��F Z)�Bp�sl�%��C/W/�I��ZV��'��v^_��S�3�,ߢlF2�OY*�Y"��T2)sJ*���vdќ���X1 A1P��%� ��������l���1������M�'�ƨU�7�C
%PDF-1.7 %���� 1 0 obj >/Metadata 119 0 R/ViewerPreferences 120 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 32 0 R 33 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]ms�������f�#�8��ͨ�;uO��m��� �"+`@4O�hw�^�w�+ 4�$b����ٽ�3{�#��� �?|���+���k������,K9�Y��^�,�^ ���募�ʗ/�~~���{�x�>/^��[}�Yx~�4N� ^3֓Z�8� Y��f� a���q�_���鈽_ � ��f�ގ/�� �V Y3�������ec.o/ǜD�)�3��繗���?M� �?�2n#G�i#C��,�������A=oI����V�ֺ��Ǘ ܈�� e�C/��6��,�n�,�q��q�x~x2O FՈpf��D �℞3�Y��C'G(�
5Alarmbio Toggle navigation About FAB Technology News Publications Vacancies Contact Building defences against aging Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a range of age-related diseases, with broad potential therapeutic application. Discover more About FAB Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a broad range of age-related diseases. Our novel approach leverages well-known, inherently safe biology with broad potential therapeutic application. Our small molecules promise to be potentia … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … site. --> News 2025 2024 2023 2022 Five Alarm Bio and Proteotype start a major grant-funded collaboration February 2025 Five Alarm Bio ha started a collaborative research project with Proteotype Diagnostics Ltd . to apply Proteotype's PCS proteome characterization technology to tracking how Five Alarm's compounds can reduce cell senescence. The project is funded by a grant from The Babraham Research Campus . See here for more information. Five Alarm Bio presents latest resea … e latest results from our research. Five Alarm Bio is awarded Green Impact Gold Award. July 2024 Five Alarm Bio is proud to have been awarded Gold by the Babraham Research Campus Green Impact scheme for our contribution to sustainable research See here for more details Five Alarm Bio starts collaboration on cognitive decline June 2024 Five Alarm
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Five Alarm Bios raises £500k for anti-ageing treatments × Register for Free Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience. Register Already have an account? Log in Skip to content Subscribe News Insights Insights Interviews Opinion Analysis Tech Hubs Tech Hubs London North East West Midlands Wales South East North West East Midlands Scotland South West East of England Yorkshire & Humber Northern Ireland Reports Podcast Events Jobs Login Log in Subscribe Login to remove this ad Health Tech Five Alarm Bios raises £500k for anti-ageing treatments He … e-associated diseases.” The seed funding follows a £360,000 Biomedical Catalyst grant from Innovate UK, given to the company in February last year. Topics Cambridge Angels Five Alarm Bios Innovate UK Meltwind o2h Ventures SyndicateRoom Register for Free Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience. Register Already have an account? Log in Most read Opinion What politics can learn from a growth CEO’s playbook Tue 16 Jun 2026 Opinion Move
#biotrinity #lifesciences #innovationdistrict #vr #scienceislife #oxford #oxfordnorth | Oxford North LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Portfolio – 5AM Ventures Company Facts Members Involved Visit Website Portfolio Strategy Team News Careers Contact Investor Login Portfolio Strategy Team News Careers Contact Moving healthcare forward 5AM’s portfolio of advanced life science technologies is diversified within the healthcare industry’s biopharmaceutical, drug delivery technology and research instrument sectors. We support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. Our portfolio companies spearhead novel approaches to diagnose, prevent and treat a … uot;adaptive" window technology for residential, automotive and commercial application. Homology Medicines, Inc. (FIXX) translates proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases. IPO - March 2018 Ideaya Biosciences uses small molecules as novel personalized cancer therapies, leveraging direct targeting of oncogenic pathways and synthetic lethality – an emerging class of precision medicine target
%PDF-1.7 %���� 633 0 obj > endobj xref 633 39 0000000016 00000 n 0000002488 00000 n 0000002619 00000 n 0000003807 00000 n 0000004515 00000 n 0000004669 00000 n 0000004706 00000 n 0000004827 00000 n 0000004941 00000 n 0000005052 00000 n 0000005722 00000 n 0000006310 00000 n 0000006990 00000 n 0000007596 00000 n 0000008134 00000 n 0000008699 00000 n 0000009177 00000 n 0000009690 00000 n 0000009774 00000 n 0000009900 00000 n 0000010497 00000 n 0000011066 00000 n 0000011727 00000 n 0000012295 00000 n 0000012909 00000 n 0000017742 00000 n 0000017873 00000 n 0000020531 00000 n 0000025795 00000 n 000 … @� �I���h��ߊ0 [e�2*H����I��t��O ]ms�?jX��a� > endobj 662 0 obj >stream application/postscript CWOD-newideas-Final (Tammy Ward) 2024-05-03T10:11:24+01:00 2024-05-03T10:11:24+01:00 2024-05-03T10:11:24+01:00 Adobe Illustrator 27.9 (Macintosh) xmp.iid:12cfa553-9925-4140-bea9-84c00d8b9ab0 xmp.did:12cfa553-9925-4140-bea9-84c00d8b9ab0 uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:83176075-c000-4e76-bcc9-4f3faf977466 xmp.did:83176075-c000-4e76-bcc9-4f3faf977466 uuid: … a 2023-05-25T10:29:39+01:00 Adobe Illustrator 27.4 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:9e3391aa-8267-4a24-88b6-f6cd50d07a7b 2023-06-27T09:52:04+01:00 Adobe Illustrator 27.5 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:ed53f858-d1e2-4e45-a832-e143063ca385 2023-10-17T10:06:23+01:00 … 6 2023-10-19T23:34:26+01:00 Adobe Illustrator 27.5 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:12cfa553-9925-4140-bea9-84c00d8b9ab0 2024-05-03T10:11:24+01:00 Adobe Illustrator 27.9 (Macintosh) / Print Adobe Illustrator False False 1 506.792539 226.648885 Millimeters Cyan Yellow Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 226 6 19 CMYK Yellow RGB PROCESS 255 236 … p��d�͆��ɸ��tYi�s�E���*�ih�_?=���AG�Xtzhz 1g�5��x& ��q� ,4\}������/ >stream application/postscript CWOD-newideas-Final (Tammy Ward) 2024-05-03T10:11:24+01:00 2024-05-03T10:11:24+01:00 2024-05-03T10:11:24+01:00 Adobe Illustrator 27.9 (Macintosh) xmp.iid:12cfa553-9925-4140-bea9-84c00d8b9ab0 xmp.did:12cfa553-9925-4140-bea9-84c00d8b9ab0 uuid:5D20
Five Alarm Bio - o2h Ventures Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contact Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contact Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk … e Therapautics Area Anti-ageing Headquarters Cambridge, UK Investment Portfolio Fund Investment Co-Investors Co-Founder June 13, 2024 Five Alarm Bio Partners with Babraham Research Campus on Aging Biology Research February 28, 2023 Five Alarm Bio Ltd Secures £500K in Seed Round February, 2022 o2h Ventures portfolio company Five Alarm Bio wins £360,000 Biomedical Catalyst grant March, 2022 Five Alarm Bio's test molecule shows anti-aging effect July, 2022 Five Alarm Bio ap … connect with us linkedin twitter --> youtube email Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums. Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risk
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Start, Scale And Grow In Stevenage – Eight Health Innovation Start-Ups Graduate From Stevenage Bioscience Catalyst’s 2025 Business Accelerator | Stevenage Bioscience Catalyst Skip to content Search for: About Board and Team Contact Us Getting Here Careers Stevenage Ecosystem Campus Who’s Here Support Business Support Scientific Support Space Accommodation Lab Hotel Incubator Building Spark Building Accelerator Building Amenities News Latest updates Events Publications Sustainability Accelerate Start up Alumni Members About Board and Team Contact Us Getting Here Careers Stevenage Ecosyste … the programme, all graduates received a complimentary CRO support package from award-winning partner Pharmidex. Ash Alavijeh, Director of Operations at Pharmidex, said: “It’s been a pleasure to support such an inspiring group of entrepreneurs. We believe strongly in providing hands-on, practical support to early-stage companies, and this partnership with SBC is a perfect example of how industry can play an active role in strengthening the innovation pipeline.” Paul Witcombe, … s programme to life. Discover more about the SBC Catalyser programme and how to apply here . sureyya hilmi 2025-06-30T17:02:44+01:00 News | Share This Story, Choose Your Platform! Facebook X Reddit LinkedIn WhatsApp Telegram Tumblr Pinterest Vk Xing Email Newsletter Newsletter Copyright © 2025 Stevenage Bioscience Catalyst Terms & Conditions Cookie policy Privacy policy © 2025 Stevenage Bioscience Catalyst Terms & Conditions Cookie policy Privacy policy Page lo
%PDF-1.4 %���� 10 0 obj 8743 endobj 9 0 obj > stream x��{{|����9�\w7!���n.d7, �$\� �@k>| "�Y�M�QFKpv�]� �>C�$���"`l!�xL�F�X��%� ���C-��\��%8 W�ls���y�^��&��ߏ� �0�Q�����Ax ��'� ������p:n� H43�0����"+G�Z��(�� _���p� �:�|�+6y i�V�q�k|�1c�M�����[�x �+.��@�$�|���"_�����R��k|�S+� SR��|8~�k�\��t�������>E�ƹ�������4o�a�7=��US=��'T�� �t�W�o�= ��A~|~F��0ޏ0��$��ZK� �|���z�' �E�EN�ln����Z�s4��nZ4cPٴ���U���ŘV�K@��}1����!�k]E��{��gp�6��%c%4�`ڪ���R�d��9�gT�R|y�.wuaRk,4O[�^�9Kn ��j��4��+*�DD�Djo��N�1�[��9r�������I���RG�O�(h�?����F��"ҟ�� ������8�O��U�R��+ … G����>�sg�ͮ���B�� ���f�7 �� z�`S�;]Oǚ���ߛ�.��u�v�4���x��kL�~��j6v6����ss rFP�+m=zA�yf�� �2�iͬ5����V�:vl���� aZ d�`���F���0X7�!%�m�ܩ�9 ��r��k�o�_t�*+ 4褾�mG�:��M�W� �ןJ�� *�%߉��iu=m[I����;Qf�ll� �7P����Q]�*m;�g�� &�n�F��$���5��n���[�����#�Ⱥ�f� ĭ2�C��t���9 �j"�I � .��$�q��j��*�iu��)�{s�i��4k��gMi��u(���#++@=��]�(��B�4��%毯�{�l"!Uc� ��J� y0�g �/ ~- k=A��[Ib�w�!&2�d ���>�ҼWi���2Ak�.� �Ί�b���:W_E/k.��s^�xGF��.��ͻ��@�26q������EK�3�(�p�QE\.Q … ��Oj��#=�[K�'h��� �Y��C9u>j� �3ǿz*�M-�Y���I G����B�.�#�Y;�q:%�����~�JI�rFpֻ[\C���OE�&���*"�2|��8/.7�L �� Xx�2NH�==* ���q��;*��pG�VF���"�ݤc�{��q�F�_z���s�o ���GM�����ԡ�[)�˖ �x%V�q�,�8| �5j�rK����;!N7PO"� ���S�@�5~Np��l6^=�!�ѷ�?Q���4nu �=��������CY�,��$��ǐ F�q(#px�$>�;f�=�6�6$���q��R\1Y��S��q��WԘ�099��Zś�W�������J�eHU�0;Gj�q$�0���t�P�*�#y?).q�ϧ^Ԋ �i��fd��H�� ��[J�weIm��d^$��뎽9"��ku٤�}��dqH9��?BL��D��� �"�P�cu� ��@�>��R:�� �l … '�# �h����>���J-%?v����ts :�?�EN�K,D�b,4|a|�D �A�L�r�d^H:K,!fC�Q��*%�Rfp��Uw"p)��4�C� �ݑ����X(0-7!)f�x]���3d��1L т���]O�Gqd&�& #�IwH.Ô�*�ܦ�϶��m- U ���]6 ^{4������I�W���I �{�� ��. ��w ����%ҕД#���!,�d�Ohd�0��J�'��n���ԑA(ͦ�h�s� �gϫ]gզ���0%Zą�3 ��~#��HJ�-+�:�/����L7[�������^�(�ΆVO��*x� �{ � ���O,�2pl�������jx$N�x&�f]��\��\ۑ�eT��Ra0��pp�n��9ҌO��s����}�5�4ݤu:3~��`oF`Q=+zZ��mx}��U��^A�7��贁��a�99��wc�Rx�����iQ7��2��q�'�,d��NϜ�t�i��W … �Kt�uJ �~F�(k��$��}m�o->l�����z����;�3�im���|�JC[����ڻ���T���Z���%�Z]����3!Rfp)Q�B��psCZ� N˖_����;�.���s��>IUz+�3�c� Ƶ�k �Z3h�{E9C4� �UP�A�p'�X����7����u%�(���c )�P)�R�QKER�@ EI���ݴ��(�j�چ�P#b�(�0��(��(��(��(��(��(��(��(��(��(��� p=���̪E�yn������'��[ D���HL����2 d 6�8?�� ��� ng�x"��gI>�l����1��K � �\f�|%w �|�&�]����XG&% O
%PDF-1.7 %���� 1 0 obj >/Metadata 2156 0 R/ViewerPreferences 2157 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 15 0 R 24 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��XKo�@�[��# e;�}J���� �J � ��(��ٵ���-��#Evֻ3��7��6pv�����������������-/WϛV�5�XTh0b .9# ђI ?oՇp��V�삀��,� ���xL� �G�|4�C��}���� ��D?�����\nf\"FF1���b4ffń4X��Mɠ��f��0M���a2v�4M�����V� �Ȥ)j?�nj��d�6k�$H$�e��5KW# #ẽ�U��yc�'r��bC��[���[ n��E:D�j����m\5K�u�^� … �甐���� ���w�V!� :;]�}q��c8�*5�qX��>��'@� ���kS�Z��m &)�Pݛ�a�R�I6f\ )7��RFP������䄚�9@?�$���`[�FJ��2qr��M�����A��£�j� +����!|8�� 9'�kY)��9�9��-�9�3pLa��� �!��I�|�s�h��P(z+�.������T(�� s�95&�e��t)�hC��jƍ A@�E�2#B���:�R��53ʉ6D�)e+����kԊY*�=���� ��m}7+��8�=� t9qu92B���9����V����2�C4�4Pa �lYbD��5qe��Z&k\�c�[�f�����\}��٪VM%�� �� �E?.P Y�͡�m�nV���p�T+_Q�>a"��DҰ+p̨��~� 8��Lo��FM�qs�|Fv���,��R����,�B#21��I��H�0��D�"jv�:�dBIuD�K��'6ִ>̞xw … �5]#��4��C�'�M�fH.��Ww>�Q�eNI��py��kN���ק�{�Q\�HW�x�� !��G���&b�Z�n~g'�RFpA#�R�£�Љ�SZ�U7�|w�Z�ga��K�ֹ�'�:��y�n$z�5�7�r� ����}��䷌��J���H �2}��j���b'gws��M2�O����erע��a2%R~\g��Aq��'�@�Ņѽ���?׃�q���+��i���{�X�� ��YxL���X&E}�ʅY~v #��=�#H���R�dSז�덠~�Ea��߃~"�멠O�Avekv�b.����� ^� �w�t�*�z-Ѻ��xΩ �|E�/ kW�ŝ��Ʃ�H�*ȅ�C�m'� x�v�w���-smcs ���g��ǹ��Y��1�p0k�ѵx ��������[l.O�*�G� ?=r�j���у�{4�9_�x�R����6Y�+�ZD$E�#�;�x����)�?��-�U��4�-�� … ]�&�W�mG����?��� My�����m;� 3U�FJ�9�Ԕ�i��� p'5�P*�!���K�|GP�M0s��DΖ(�b5�D�rfp��Ijv��E��`�"MU�MS�NS;5]s7PKP���D�ě�Ht'z��C( ��%.��o�#��"�� �������z:"���"=m�����a��#�nB-A��7���A"A���)}B ���{e��H �'�z�rY�D���P6~}E����9~��d۱>�� ��������a��AЖW_�� �oj�����Qrx����������YM �q��8���{6�MS����.k(�]��(��5�8 e6�� k�u�\ �"Ox;;��� #2>��o�3,"����]{�]�J��}�;�r7z �Kp!�ܣeFpaެ�R�ʼna�� #k"�����δ� ʱGEǝ����4_ �F��� ��G$P�P+�M ����������������6v67v4 x�
%PDF-1.7 1 0 obj > stream x���iP��ow��-Y¾�M���-���l��a �]Q�ED\@E ptXdQ�T\� �88�*� t�MիW���}�������nD0r�Ţ`_OzDd � Ƀ9q�i��}�w��ow���ܙ� �tT��Y��P��x� .����X���@��B� )B��M�8an�!� l>����m��m�Þ�k��d�� � @�-�D�9 C�n@DN�Ԁ�ƀl�p����@ "�j� �@��� /���K�'� �~�s� A�`@p"x���"B ��p�0F�!*��.�Pb"q+���@�L|H|C"�tI���$i ��t�t�4B�HV"��Y�h����|��I�O~C�P )�(����RG�DyL� G���c���6�U�5��˽�'��{ȯ�_'_*V����A�P���QؤP�pNaHaZ��h����X�xR��N�P�[����tL��(Eգ��\�6j �2u����شDZ�'Z/mJYI�V9L9[�B���T�b��VIV)R9�2��i�����4,�_�^u���*_5_�Qu@��]�[-Im�Z��#u����r�,���
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Search results | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect with future talent Boost your job Tips for finding a job More Contact us Join the network My profil … e Science 13 Jan 2023 CUH neurosurgeon wins prestigious Hunterian Professorship award A consultant neurosurgeon from Addenbrooke’s Hospital has been given a prestigious award for his cutting-edge research into traumatic brain injury. Tom's Trust Charity and Social Care , Healthcare and Life Science 13 Jan 2023 Tom’s Trust spread Christmas cheer to children in hospital From superhero capes to books and cuddly soft toys, children were treated to some wonderful gifts from T
News Approach Technology Pipeline About About Octant Blog News Careers Octant Careers Apprenticeship Job Openings Contact News & Press Octant Announces Collaboration with Foundation Fighting Blindness to Expand Uni-Rare Natural History Study with New RHO Cohort April 22, 2026 Foundation Fighting Blindness Octant Announces Collaboration with Foundation Fighting Blindness to Expand Uni-Rare Natural History Study with New RHO Cohort April 22, 2026 Foundation Fighting Blindness Octant Announces Collaboration with Foundation Fighting Blindness to Expand Uni-Rare Natural History Study with New R … es for Neurodegenerative Diseases November 12, 2025 Octant Octant Awarded $4.9M Grant to Launch HPV-Driven Cancer Therapeutics Program June 11, 2025 Octant Octant Awarded $4.9M Grant to Launch HPV-Driven Cancer Therapeutics Program June 11, 2025 Octant Octant to Participate in AI in Drug Discovery Panel at the Jones Healthcare and Technology Innovation Conference April 9, 2025 Octant Octant to Participate in AI in Drug Discovery Panel at the Jones Healthcare and Technology In … positions December 12, 2023 Octant Octant wins "Technology and Tools" Award at Mutational Scanning Symposium 2022 June 13, 2022 See Octant poster presentation on Deep Mutational Scanning Octant Octant wins "Technology and Tools" Award at Mutational Scanning Symposium 2022 June 13, 2022 See Octant poster presentation on Deep Mutational Scanning Octant Octant: leveraging cell barcoding for small molecule design April 22, 2022 BioCentury Octant: leveraging ce
UK - List of Biotech, Pharmaceutical & Life Sciences Companies About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact United Kingdom - Biotech Company List Order by: Company Name - Location UK - Nottingham Providing a full range of drug product (CDMO) and clinical (CRO) services, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast. UK - Oxford A CRO built to deliver faster Clinical Trials. Optimapharm is a global CRO with integrated therapeutic platforms and 2x NA/
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mult … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Search results | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect with future talent Boost your job Tips for finding a job More Contact us Join the network My profil … armaceutical company to develop novel formulation of peptide therapy Partner to fund development work with option to acquire rights to proprietary formulation under Arecor’s technology licensing model. Arthur Rank Hospice Charity Charity and Social Care , Communications , Other 12 Mar 2025 Arthur Rank Hospice charity celebrates personal best in the TTP Cambridge Half Marathon 95 dedicated runners supported Arthur Rank Hospice Charity in the TTP Cambridge Half Marathon. Zyme C … on Trust Healthcare and Life Science 10 Mar 2025 Trainee surgeon scoops coveted award An Addenbrooke’s doctor who is in the final stages of training to become a vascular surgeon has been given a prestigious award for her research. Cambridge Enterprise, University of Cambridge Cleantech and Environment , Education , Healthcare and Life Science , Knowledge Intensive Services 10 Mar 2025 Highlights from another great year for Cambridge Enterprise The Cambridge Enterprise Annual … Cambridge Network Limited Other 10 Mar 2025 Cambridge businesses encouraged to apply for a King’s Award for Enterprise At a recent meeting at Marshall of Cambridge, Julie Spence OBE, QPM,BEd, LLB, MA, MBA., HM Lord Lieutenant of Cambridgeshire, spoke about the multiple benefits companies can gain by the recognition this prestigious award can bring to an organisation. She encouraged companies to consider applying in one, or more, of the four categories: Identity Creative Ltd
Milner Pitch Day 2024 - The Milner Therapeutics Institute HOME ABOUT US Mission & Values Our Team Our Facilities Milner Boards Careers & Opportunities RESEARCH Target Discovery Functional Genomics Screening Laboratory AI and Computational Research PARTNERSHIPS Therapeutics Consortium Consortium Call Partnerships & Affiliates ENTERPRISE Bio-incubator Enterprise Initiatives NEWS Latest News Milner Newsletter EVENTS Events Calendar Annual Symposium Symposium Overview Symposium 2026 Symposium 2025 Milner Pitch Day Pitch Day Overview Pitch Day 2026 Pitch Day 2025 Milner Seminar Serie
#o2hventures #o2hchaitime #portfolio #eis #seis | o2h Ventures LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privac … - A Look Back at 2024 & Exciting Updates o2h Ventures 1y o2h Ventures SEIS Fund May'24 Update o2h Ventures 2y Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Real Estate Marketing Sales Retail & Merchandising Science Supply Chain Management Future Of Work Consulting Writing Economics Artificial Intellige
Investment - Page 8 of 12 - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell … n rare disease therapy UK biotech firm SynaptixBio has secured £13.2 million to fund its development of the world’s first treatment for TUBB4A-related leukodystrophy, a rare, incurable and deadly disease. The company successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the… Read More 14 April 2023 #Business & Investment #News #Cancer research #Funding #Investment #Mosaic Therapeutics #Oncology #Wellcome Sanger Institute … ons. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company… Read More 16 March 2023 #Business & Investment #News #Cancer research #CureLab Oncology #Gene therapy #Investment #Oncology #Plasmid DNA Oncology company receives $3M from biotech investor Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The t
%PDF-1.6 %���� 38516 0 obj > endobj xref 38516 33 0000000016 00000 n 0000015429 00000 n 0000015801 00000 n 0000016312 00000 n 0000016640 00000 n 0000017101 00000 n 0000017215 00000 n 0000017492 00000 n 0000018001 00000 n 0000019090 00000 n 0000019206 00000 n 0000019247 00000 n 0000019634 00000 n 0000019912 00000 n 0000063998 00000 n 0000105751 00000 n 0000111481 00000 n 0000114133 00000 n 0000122475 00000 n 0000131950 00000 n 0000134130 00000 n 0000140417 00000 n 0000140681 00000 n 0000141047 00000 n 0000144632 00000 n 0000298402 00000 n 0000307002 00000 n 0000362180 00000 n 0000367923 00000 n … ߚ�8U� h�r�� Hy�4�ڤK�k�y���9y���tʢ�!��y�P�� � @��d�Xصs e*jz��~�n�A>v�D���"RfP�q^�����2�gN��/��-)���)�J��Q+��2� LLE"\\a�[u�o�*e�f����KDP���j9��r�52�7)��� 2�(�q�Ɩ a��N��0�QR-N�+D��v�x�:~z�L��WDP� w�o�9�R�OTZuc���4�)䂍��0� ����˔D��LENQP/)@Ge��3%*�IJ���R�O�H��� uU �cKO2r�������\S���Dqǐyk*K � ����b�� ����M�x'� ԓ&n�*I�}P��3b ���\>�h;3� K�^W�-��hYt������)�p��6���L�p{���6��f�%ckR�+7fGV�GT2����R@��u�aUc�� q�% 1��d]kN���et�b��)�N\ �!������ … ߚ�8U� h�r�� Hy�4�ڤK�k�y���9y���tʢ�!��y�P�� � @��d�Xصs e*jz��~�n�A>v�D���"RfP�q^�����2�gN��/��-)���)�J��Q+��2� LLE"\\a�[u�o�*e�f����KDP���j9��r�52�7)��� 2�(�q�Ɩ a��N��0�QR-N�+D��v�x�:~z�L��WDP� w�o�9�R�OTZuc���4�)䂍��0� ����˔D��LENQP/)@Ge��3%*�IJ���R�O�H��� uU �cKO2r�������\S���Dqǐyk*K � ����b�� ����M�x'� ԓ&n�*I�}P��3b ���\>�h;3� K�^W�-��hYt������)�p��6���L�p{���6��f�%ckR�+7fGV�GT2����R@��u�aUc�� q�% 1��d]kN���et�b��)�N\ �!������ … ���6��[�d,��b:ۨ ��ԡ�( v� �S�1,�5Spp��A�e[���D����$�����d�n1m���R]��m ��BB�RFp �n��WIJ��Q��bIOU҆�c��K�L4c�Ҵ/ 5���ѭW�}����:��HeՄ$��-�G� ���j���5��m7��X0 �.�=���Y}j�:� ��ȗ5�N�ZH KY�Iַ�\�۰ZV�zR�JqY �;����r ��� �m�LLr#�`Ā�^ p�խa?";,۵#`��Ԡ'���'�'hʒB@ �Q�FFR�L���H����ߔ:7��\���8���%�͋gk����m�>DE��E�ci�V�!�q0f�� 0�� Ե�[B�zd'���{08LK]ȝ.��F��>��8�.�+�ySbI� �ȑ��HS� ��@ 8sj�ZN�RP����dg���~��vh�,H�'�e��uM���K�n�:���vɾ�-�|�}�h�x�jxͬ"������dGJCj+�R ���z … ��7u]4B�Σ�pl�U��Yt�#��ᦳ�p�""�&�I-��uY4]�"Y�H�g��) �izi�P@;Ԕ�2�P3?����RFP�]Jd-uA\6��)��>:2�10��q;��3%*�n �D� �� n��2U1�ɉ��鄴)�D}��ڲ4ޛ�� N����e���j�qp�ei'��w�$�2����5k��^4ڒ𣱫�6�T�3�)j�K4ύ��p�8ɗ㭯16�-�3i�uXq�K��i�"Fs��(vh�h3��;:%�e�nt%��Ɋ*��W�`Cxq�- �����ك�|���Y���Q�\��i��F��f�҅yҚ>�+Y,��S诹���?���ћZ��!�e4�� �+)�J�d��
Attending Organisations | Genesis Attending Organisations | Genesis Skip to content Maximising Returns from Life Science Innovation | Thursday 10 December 2026 | London, UK What’s On Conference Programme Awards Company Showcase Exhibition 1-2-1 Partnering at Genesis Sponsor & Exhibit Sponsor & Exhibit Floor Plan & FAQs About Our News Genesis Comms Advisory Panel Attending Companies Conference Collaborators Venue & Accommodation Contact Us Register Here Attending Organisations Who Attended Genesis 2025? Attending Organisations See the organisations that registered for Gene
New partnership looks to improve cell reprogramming methods for healthcare benefits | Babraham Institute Babraham Institute Research & Facilities Discovery science to improve human health and wellbeing Our Research Healthy Ageing Research Groups Epigenetics Immunology Signalling Open Science Research Integrity Animal Research Annual Research Report Research Features Research Publications Science Facilities Bioinformatics Biological Support Unit Flow Cytometry Gene Targeting Genomics Imaging Mass Spectrometry Enterprise Supporting Industry Engagements Collaborating with Industry Consultancy … about genetic stability and safety. Supported by a UKRI-BBSRC Campus Innovation Award (CIA) via the Babraham Research Campus Collaboration Fund to Maria Christophorou, a group leader at the Babraham Institute, and Ashley Barnes, Chief Scientific Officer at Axol Bioscience, the project will test the effectiveness of novel protein modulators to drive cell fate decisions and explore whether reprogramming can be achieved with reduced reliance on the Yamanaka transcription factors … it through the efficient generation of safer material for regenerative medicine application and drug discovery. Ashley Barnes, CSO, Axol Bioscience, said: “This project will work at the forefront of iPSC technology and advances our strategic goal of developing human models for drug discovery, allowing us to move more quickly towards treatments for diseases such as Alzheimer’s.” By applying discoveries from the Babraham Institute to the commercial life science environment, thi … real-world impact for health. Two patents have been filed on this work: Patent application No. WO2024084243A1 (and related patents/patent applications) entitled ‘Novel reprogramming method’ and Patent application No. WO2025003712A1 (and related patents/patent applications) entitled ‘Novel reprogramming activators and methods’. This collaboration is another example of Campus-based teams leveraging each other's expertise and resources to maximise the impact of their research e … , through Institute Strategic Programme Grants and an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities. About Axol Bioscience Axol Bioscience is the leading manufacturer of functional iPSC-derived cells and provider of outsourced services to supp
PRESS RELEASE: CWOW Ventures Tour to provide exposure to the latest ideas in a first-of-its-kind Cambridge life science/biotech showcase - cambridgewideopenweek Skip to content Title Sponsor cambridgewideopenweek Explore the city’s world-class science and technology facilities all in one day… Accomodation News FAQs Gallery 2025 Sponsorship Contact: [email protected] About Week schedule Sponsors & Partners Register Now Title Sponsor PRESS RELEASE: CWOW Ventures Tour to provide exposure to the latest ideas in a first-of-its-kind Cambridge life science/biotech showcase 27 th May 2025 CWOW V
Oxford Drug Design CEO, Founder, Key Executive Team, Board of Directors & Employees Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Par … outs & investments. In 2019, Sunil won the UKBAA Angel Investor of the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences industry in the UK. Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer Research UK (CRUK). He is also a non-executive director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board Observer or investor of: Phoremost, Exona … outs & investments. In 2019, Sunil won the UKBAA Angel Investor of the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences industry in the UK. Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer Research UK (CRUK). He is also a non-executive director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board Observer or investor of: Phoremost, Exona
An industry leader’s perspective on the complexity of scientific data | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and
July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio - o2h Ventures Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contact Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contac … f something goes wrong. Take 2 mins to learn more July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio Aug 1 2022 Amid the ongoing debate about who will be the next Prime Minister of the UK; it will be important that whoever eventually wins continues to invest in building the UK Biotech ecosystem. Reflecting back on the last month for o2h Ventures, we are pleased to announce the successful closing of the o2h human he … we are pleased to announce the successful closing of the o2h human health SEIS Fund. We executed three deals in the last month with one investment in the SEIS Fund and two investments in the KI EIS Fund. Industry Update: According to the latest report published by UK Business Angels Association published July 2022, there is a knowledge gap among investors in ‘science and innovation’ which is compounded by the lack of progressive angel groups around university clusters that h … sessment of the viability of the biotechnology and the business. See our KI EIS Fund .. Deals Executed: Alevin Therapeutics – We lead an investment close to £1 Million from our SEIS and EIS fund, alongside co-investment from the University of Nottingham’s Invention Fund, into Alevin Therapeutics. The Nottingham University spin-out aims to develop assets for therapeutic applications based on their RGD Integrin platform; in particular idiopathic pulmonary fibrosis (IPF), … made a follow-on investment from our Knowledge Intensive (KI) Human Health EIS fund into Neurofenix: a revenue-generating digital therapeutics company developing technologies to support patients rehabilitating from Stroke. Earlier, we invested in their seed round and since then the company undoubtedly has made significant progress on both develo
%PDF-1.7 %���� 1 0 obj >/Metadata 355 0 R/ViewerPreferences 356 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 16 0 R 19 0 R 20 0 R 21 0 R 23 0 R 26 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��ZYo�F~��0}��xͽxA�ڹ�&M\���#Q�rIɮ���� ���+ ����|3����~���4 �������baV� $�N��1`U$�c��,( �B�� �?� ���� �m{����?~� G�}��O�>\�ygp��Bّ�rG���-,+��|~y28{)�&��)Y��?�rR���\� ��s����@7�O\� ����� ���#�)>��T���Y=�+U���[w=|OG})���?8��&�D����qMb����u@� ,1X$}a*�-u]��b�
Oxford North proud to be Gold Sponsor of OBN’s BioTrinity 2025 | News | Oxford North About About Oxford North Masterplan ESG Engage Meet the team Location Overview Amenities Workspaces Offices & labs The Red Hall 1 & 2 Fallaize Street Phase 2 buildings VR tour Homes News Jobs Contact us news Labs Oxford North proud to be Gold Sponsor of OBN’s BioTrinity 2025 28/03/2025 For the third year running, Oxford North is proud to be a Gold Sponsor of BioTrinity 2025 , OBN’s flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. This year’s ev
Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment - Pharmafile About us Advertise Contact Follow Follow Follow home News News Press releases Features Features Thought Leadership White papers Case studies Appointments Business Sectors Business Services Manufacturing and Production Medical Communications Research and Development Sales and Marketing Webinars The Pharmafile Brief January/February 2026 – The Pharmafile Brief December 2025 – The Pharmafile Brief November 2025 – The Pharmafile Brief October 2025 – The Pharmafile Brief September 2025 – The Ph … h support from KPMG Acceleris. This funding follows a £360K Biomedical Catalyst grant from Innovate UK, awarded to FAB early last year to develop its technology as a treatment for chronic wounds. Based on breakthrough advances in understanding of how age-associated chemical damage accumulates in cells and tissues, FAB is developing an innovative small molecule approach aimed at boosting our defences as we age, to ultimately extend the healthy lifespan of our bodies. Ag
--> Verifying that you are a human... Please refresh the page to continue (if it does not automatically refresh). If you still see this page even after refreshing, try enabling JavaScript and/or cookies in your browser.
%PDF-1.7 %���� 1 0 obj >/Metadata 64 0 R/ViewerPreferences 65 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.2 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\�o��n���>���'R� ����iz �&�@�:[���[;Zo6�{��vf�IQ����h.k�$>�3�� ������w��\$��o��]���˯���*9�8O~�+��J�����G��x�9ˊ����O2��s��:� �'o?B�������Q���]��>>�y���J�����Z�;��\~G���bE�����r��Qyɚ&�d��FE��c��O���tY,�$��)/ �e�h���R� ���=>xH%�} Ş�z���J^����4�6�:�8%g\�^H�:O�͢�� |�� XUk�\�!g�Td�W�gĻ����C1.J� |��7CV.���U J���
citybuzz : Washington DC : Mergers & Acquisitions Washington DC Search Share Your News Mergers & Acquisitions Posted on 4/28/21 Harris Williams Advises CIS Secure Computing on its Sale to HKW Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised CIS Secure Computing, Inc., a portfolio company of Acorn Growth Companies, on . . . Posted on 4/28/21 CGI To Acquire Sense Corp CGI (NYSE: GIB) (TSX: GIB.A) today announced its intent to acquire Sense Corp, a professional services firm focused on digital systems integration and consulting for … rma, Inc. (Nasdaq: SNCA), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and . . . Posted on 4/26/21 The Hilb Group Announces Four Acquisitions Henrico County-based insurance company The Hilb Group LLC (THG) announced a series of acquisitions in the last three weeks, bringing its total offices to more than . . . Posted on 4/23/21 Steward Partners Acquires Umpqua Investments Steward Partners Holdings,
William Bains Country: UK William is an academic and entrepreneur. After an academic career in UK and the USA, he joined PA Consulting Group in 1988, and Merlin Ventures in 1996. In 1999 William founded Amedis Pharmaceuticals Ltd, (which was later acquired by Paradigm Therapeutics). He has founded four other biotech companies, has helped create over 10 others, helping to raise over £60M in early stage funding for UK biotech start-ups, as well as sitting on the Advisory Boards of the SULIS Fund, Iceni Fund and Bath Ventures. His latest start-up, Five Alarm Bio Ltd., is developing therapeutics t
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
International Women’s Day: Female life science leaders - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies M … s to attracting women to its workforce. In its ‘Women in Business 2022’ report, Grant Thornton reported that at 39%, the healthcare industry had the highest proportion of women in senior management out of the 15 industries surveyed. 1 However, this progress seems to have stagnated and there is still a long way to go before women are represented at the same level as men. It was recently reported that the UK ratio of women working in R&D compared to men is almost unchanged … Founder and CEO, BioGrad In 2021, Dr Kenny won EVA’s Businesswoman of the Year award, The Business Desk top 50 City Region Leader for Liverpool and The Business Desk’s North West Investment Award. She has also been awarded the 2022 Liverpool Women In Business, Woman of the year Award. In January 2023, the company opening the second largest Biobank in the UK, which will give parents the chance to preserve their stem cells within the North West and the provision of non-invasiv … ul stew of ideas. It’s kind of magical.” On receiving the BIO Rosalind Franklin Award for work in the biobased economy and biotech innovation, she said: “It’s only recently that Rosalind Franklin started receiving due credit for her tremendous contributions to Watson and Crick’s Nobel prize-winning work on DNA structure. I am privileged to live in a different time, in which my contributions are more likely to be recognised. I owe so much to Franklin and many others.” Dr Fiona … omen to take executive leadership positions.” Winning the battle for talent The Grant Thornton ‘Women in Business 2022’ report concludes that women are thriving in the life sciences industry, but cautions that the sector cannot rely on past performance. “If life sciences businesses are to maintain their competitive edge, all the signs are that th
Digitalis Ventures | News About People Human Health Animal Health News Notebook The Digitalis Group: Digitalis Ventures Digitalis Commons © 2026 Digitalis Ventures ALL NEWS LIFE SCIENCES NEWS HEALTH TECHNOLOGIES NEWS ANIMAL HEALTH NEWS DIGITALIS VENTURES NEWS Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. VARDA 5.13.2026 A plan to make drugs in orbit is going commercial MIT TECHNOLOGY REVIEW > EPIBIOLOGICS 4.20.2026 EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors BIOSP … ANCE > ONC.AI 10.24.2024 Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC BIOSPACE > Alpha-9 Oncology 10.23.2024 Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals CNHI NEWS > TERRAY THERAPEUTICS 10.21.2024 Terray Therapeutics aims for the clinic by 2026 C&EN > TERRAY THERAPEUTICS 10.17.2024 Terray … genomes Nature Biotechnology > DIGITALIS VENTURES 10.25.2023 Mars Companion Fund to take bigger bets on petcare startups GLOBAL CORPORATE VENTURING > Native Pet 10.16.2023 Native Pet launches new all-in-one supplement Pet Food Processing > Faeth Therapeutics 10.13.2023 Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee Business Wire > Eden Brew 10.11.2023 Eden Brew alternative milk startup attracts $25m i … Wire > DIGITALIS VENTURES 10.3.2023 Mars and Digitalis Ventures launch $300m Fund to improve the lives of pets… MARS > Terray Therapeutics 10.2023 A New Molecular Language for Generative AI in Small-Molecule Drug Discovery NVIDIA > GRO Biosciences 9.27.2023 GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies Business Wire > PetMedix 9.19.2023 More animal magic as Zoetis acquires PetMedix in Cambridge Business Wee … ces 4.11.2023 GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship Business Wire > Switch Therapeutics 3.14.2023 Switch Therapeutics Raises $52M in Series A Funding FINSMES > Code Ocean 2.17.2023 Code Ocean Partners with Nature Portfolio to Launch the Open Science Library with Ready-to-Run Software from Authors in Na
PE Weekly: Healthcare Tech, Services Come Back Into Focus | ACG Insights (Formerly Middle Market Growth) About Advertise Subscribe // ACG About Advertise Subscribe // ACG Magazines The Latest Multimedia Podcast Video Sectors Manufacturing and Industrials Technology Healthcare Consumer Products Food and Agriculture Business and Financial Services Next Target Deal Stage Business Development Due Diligence Deal Execution Value Creation Exit People 2026 BD Pros to Watch Home News & Trends Latest News PE Weekly: Healthcare Tech, Services Come Back Into Focus PE Weekly: Healthcare Tech, Services … l acquire the company. Fundraising 26North Raises $5.9 Billion for Inaugural PE Fund. 26North Partners announced the close of its inaugural private equity fund with $5.9 billion in capital commitments, surpassing its initial $4 billion target. The fund will focus on investments in middle- and upper-middle-market companies, and has already completed seven equity investments. Topspin Raises $328 Million for Consumer Investments. Topspin Consumer Partners, a private equity firm … umer Partners, a private equity firm focused on the consumer sector, closed its Fund III with $328 million in capital commitments. The firm said Fund III will continue to focus on investing in health and wellness, personal care, beauty, food and beverage, household goods, and pet, among other consumer-focused verticals. Middle Market Growth is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.ac
Episode #7: Dr Janette Thomas ... - Cambridge Gravity Encounters - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ٨ ديسمبر ٢٠٢٤ ٤٨ د Episode #7: Dr Janette Thomas - CEO, Five Alarm Bio Cambridge Gravity Encounters تشغيل Today, we have the pleasure of speaking with Janette Thomas whose journey took a fascinating path from the world of dance to the heart of science. Our guest started her career as a dancer but soon found her passion for science, leading her to pursue a degree in the field. She went on to complete a PhD in Biochemistry at the University of Leicester, followed by a postdoc at t
Janette Thomas, Five Alarm Bio - Careers in Discovery - Apple Podcasts Search Home New Top Charts Search October 25, 2023 45 min Janette Thomas, Five Alarm Bio Careers in Discovery Play "I realised that drug development was much more than just research. There's a huge amount of work beyond coming up with a molecule, but research scientists just don't get exposed to it." Janette Thomas has built a career from Researcher to Project Manager, Operations Director and now CEO of Five Alarm Bio, a company focused on novel approaches to anti-aging. Janette joined us to talk about the current state of
%PDF-1.7 %���� 1 0 obj >/Metadata 137 0 R/ViewerPreferences 138 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 21 0 R 29 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]I�#�q�7���GI�+�,� �r �dL>> 3 4�d�8�Ȍ��"��U���cU��������4K}p�MJ �4���d�>��ϟ��O��?:|����p:}��۟����������� �34�]�Z� �իRW�Ô~�j�:���ݡ�r����=\��K��y!�SP��ӓ[Y?e��Q�5y{PFM�9̓�R��?�ܩ7�Nn�Q*[s���H�G%�ik�� 7�EtZ��3-� �۫U��,�����˜>����)Y�yR�� �%1�̆�%��Da����惲/g� o�� ����l�)#f���g
Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Br … ort from KPMG Acceleris. This funding follows a £360K Biomedical Catalyst grant from Innovate UK, awarded to FAB early last year to develop its technology as a treatment for chronic wounds. Based on breakthrough advances in understanding of how age-associated chemical damage accumulates in cells and tissues, FAB is developing an innovative small molecule approach aimed at boosting our defences as we age, to ultimately extend the healthy lifespan of our bodies. Age-relat … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel
%PDF-1.7 %���� 1 0 obj >/Metadata 218 0 R/ViewerPreferences 219 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.2 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]Ks9��;���{ 7��*���p�����m{��=�%q-J R�G�g��"�*$e�Ph�,��$2�L$P�/�g�����o_f�������?�>)��kۺˊ�ꪜe�(�e���'�{v����ǧO~y]f \�x��I)�[d�� &��f����[��7 ��b/8��w�~���O����/��Շټ�����Ϲ�s�?������O��O^I�����h K���yD�4GYH-{��E�y�*S���7����[^e W�f�I,[�u ' �W;�;�b9/Kx���>�ؗM^6G��,����1�@��%On�M���I:0r�(#gY v�r9��i>x2>x'�g
Business of BioTechniques 2023 - BioTechniques Skip to main content BioTechniques is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Journal Aims and scope Current Volume Editorial board For authors Your editors: what do we do? Follow us on social media News Latest news Tech news Events news Company n … 7A and ICH S7B guidelines, is an important step in the Investigational New Drug application process for potential small-molecule therapeutics. Orano Med and Orbit Discovery enter collaboration to discover novel targeted radioligand therapies for cancer Orano Med (Texas, USA), a biotechnology company developing lead-212 targeted alpha therapy against cancer, and Orbit Discovery (Oxford, UK), a leader in the discovery of therapeutic peptide hits, have entered into a collaborati … cience Ann Cleves join the Optibrium team, respectively focusing on R&D and application science in the newly created BioPharmics Division. H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development H.E.L Group (London, UK), a global developer and manufacturer of innovative laboratory tools for process optimization, safety and scale up, has signed an agreement with the Indian Institute of Technology Kanpur (IIT Kanpur; India), a prestigious acade … luding bowel cancer and lymphoma. Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning (ML) Intellegens (Cambridge, UK), a company applying ML to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation, to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI; Redcar, UK), the t … £1.9M grants awarded comprising the recent Innovate UK New Cancer Therapeutics award of £1.6M and a previous Innovate UK Accelerator grant of £300,000. People CN Bio appoints Tomasz Kostrzewski as Chief Scientific Officer Ubiquigent appoints Rishi Shah as Head of Chemistry July update The latest Business of BioTechniques blog outlines financing
Gilead has acquired MiroBio for $405 million about sponsor subscribe subscribe Thank you! Welcome to Cambridge Biocapital. Oops! Something went wrong while submitting the form. Make sure you submit a valid email. 020 Gilead has acquired MiroBio for $405 million. Vicebio has emerged from stealth raising $18 million. Eleven Therapeutic has raised $22 million seed funding. Aug 5, 2022 Gilead has acquired MiroBio for $405 million. AUG 5, 2022 | 020 Summary Startup Funding News Investment Funds & Accelerators Startup & Science News Talent & Operations Pharma Afffairs Podcasts & Inte … iv-based Eleven Therapeutics has raised $22 million in seed round in equity and grant funding. The round has been participated by the Gates Foundation , Kindred Capital , NFX Bio (former TechBio ), Harel Technology Investments and Entrée Capital plus an Innovate UK Smart Grant . The proceedings of the round will be used to advance the company’s proprietary AI-enabled drug discovery platform capable of designing siRNAs with improved half life. In addition, the platform will be … g. The round was led by FabCapital and participated by the Microsoft ’s venture fund M12 , Quiet Capital , Lunar Ventures , Alter Venture Partners , re.Mind Capital , Fluxunit and Charlie Songhurst . iLof (Intelligent Lab on a Fibre) was founded by Mehak Mumtaz (COO) and Luis Valente (CEO) and has secured $8 million in funding to date. The company is developing a photonics and AI- powered platform to accelerate personalised drug discovery and development. The company analyses … been co-invested by o2h Ventures and the University of Nottingham’s Innovation Fund . Alevin Therapeutics was founded in March 2022 by Thomas McInally (ex- AstraZeneca , Fisons ) and Prof Chris Moody (ex- Roche , former Sir Jesse Boot Chair of Chemistry ) experts in the field of RGD integrins and it is working to develop a small molecule RGD integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), kidney disease and related cancer. The proceedings of the … s oral drug for liver and kidney fibrosis. BIOS Health has secured $1.4 million grant funding from MEDTEQ+ , the pan-Canadian Consortium for Industrial Research and Innovation in Medical Technology, the Ministry of Economy and Innovation of Quebec , Mitacs Accelerate and the Healthy Brains, Healthy Lives program at McGill University . The proceed
Longevity investment bulletin: Five Alarm Bio, Capsida, MyMD and more Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restoration chip MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity Ergothioneine: The little-known molecule tra
Deals > United Kingdom - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 New Nvi … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Five Alarm Bio–Meltwind: investment, 202302 seed financing round totalling >£500k incl investor Meltwind - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partn … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Pharma | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect with future talent Boost your job Tips for finding a job More Contact us Join the network My profile Log in
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
News - Page 238 of 408 - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Sc
The Medicine Maker | The Fountain of Youth --> Network Conexiant.com Conexiant DXP Conexiant Education Conexiant Solutions Conexiant TV Login Partner With Us --> The Analytical Scientist The Cannabis Scientist The Medicine Maker The Ophthalmologist The Pathologist The Traditional Scientist Explore Explore Latest Features Interviews Business & Trends Technology & Manufacturing Product Profiles White Papers Featured Topics Biopharma Small Molecules Cell & Gene Future of Pharma Issues Latest Issue Archive Cell and Gene Therapy Supplement Topics Topics Cell & Gene Bioprocessing Dru
Five Alarm Bio and the fight against aging diseases | Janette Thomas posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … nto the ROI analysis pharma companies go through when deciding what research to fund. This means that on average, pharma can undertake more complex R&D efforts that have a roughly 10% higher probability of failure. Getting more drugs approved, faster, all while elevating the quality of science and level of innovation is precisely what QuantHealth is all about, and it’s great to see the FDA pushing in that direction. Greg Licholai https://lnkd.in/dSN2jth9 FDA And White Hou
%PDF-1.7 %���� 1 0 obj >/Metadata 118 0 R/ViewerPreferences 119 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.2 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� ˎ��>��C ���0h`fv�p �@A���������)�J,I�C������b��/�>����~;==}����ϧ�ӟ~����_~;����rz��z��������93��� 5'�8��?�<>���� ^�<>|z�'�٠N_������É� ?Y%�u�/��˾�ў���?��5~r��w������O_����� ��LJ������� 6��H�'H#���}�6���%?���5r��;똒��a�o������?��������� ?���a����/�s����>j7p��U�˟/|X�%�/g.���������1ˍ��̈́G_���,�
Five Alarm Bio targets Alzheimer's and skin aging - Longevity.Technology Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeuti
inhite ventures --> MENU ☰ ✕ Home Carl Jones, 🇺🇸 📃 Articles 📈 Stocks: NASDAQ, NYSE 🏦 Banks 📌 SVVC Family | In Loving Memories Tran Minh Chieu, ESQ. ⚖ 🛢 O&G, 1940s 🛢 O&G, 1980s Nguyen Duy Long, CAPT ⛪️ Church Sponsors   … emic scholarships and achieved athletic awards; he was granted a full U.S. Navy scholarship to an officer candidate school (OCS). He received military training and education at the U.S. Naval War College, https://www.usnwc.edu , in Newport, Rhode Island where he achieved and held outstanding marks across the charts. In the last ten (10) years, Carl has been traveling to several cities and visiting startup communities, spending some time living in the ASEAN region and returnin … ns in 1983 under their American names and of the names of their senior American fellowship church sponsor families . The family now resides in the states of California, Florida, and Texas, and family members have previously lived in New York, Connecticut, Maryland, New Jersey, Virginia, and Washington, D.C. Having proven management experience and leadership skills in both corporate and startup environments, as well as having obtained a security clearance to work on government … lio management from early-stage to exits, M&As and IPOs; venture capital ("VC") fund formation and opportunity funds ranging from $50 to $500 million. Well connected in the “VC/startup” ecosystem and with investors; invitation to join the National Venture Capital Association (NVCA.org), http://www.nvca.org ; traveled locally and globally and can speak additional languages; established relationships and contacts in areas of media, legal, government, stock markets, … tion & Human Relations, Certificate of Recognition and received Human Relations Award and Special 100 Percent Recognition, 2002. Project Management Professional (PMP), Enterprise / Project Management Office (E/PMO), Certificate of Completion, 2001. Software Development Life Cycle (SDLC) / Lean / Agile, Certificate of Completion, 2000. UNDERGRADUA
Five Alarm Bio–United Kingdom (govt): grant, 202202– Biomedical Catalyst grant £360m from Innovate UK for developm of chronic wound treatment - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Five Alarm Bio: How Innovate UK Business Growth helped | Innovate UK East posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … e, focusing on novel approaches to anti-aging, with broad potential therapeutic application. They are researching therapeutics that boost the body's ability to defend against the damage of aging. As a spin-out company in biomedical research their Innovation & Growth specialist has supported them with identifying funding opportunities to continue their research Since working with Innovate UK Business Growth, Five Alarm Bio has demonstrated the value of their research to po … ccessfully: ✅Finalised an IP strategy through IP funding ✅Used the RTO Catapult grant to undertake research with medical professionals and academics to help refine the areas of most commercial impact for their innovation. ✅Partnered with a European University to undertake research using new materials, to allow broad patent coverage through The Global Explorers programme William Bains, Director and CSO of Five Alarm Bio said “Innovate UK Business Growth has been invaluable in
Five Alarm Bio and Proteotype collaborate on new anti-aging approach | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect with future talent Boost your job Tips for fi … Proteotype Diagnostics Ltd have been awarded a highly-competitive collaborative grant from the Babraham Research Campus from the Campus Innovation Award programme, to develop and test novel biomarkers for cellular senescence. This collaborative research effort will further validate Proteotype’s Protein Cross Sections (PCS) as a diagnostic tool for senescence, and will help to provide confirmation that the Five Alarm Bio's compounds modulate a key hub in the cell's
5Alarmbio Toggle navigation About FAB Technology News Publications Vacancies Contact Building defences against aging Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a range of age-related diseases, with broad potential therapeutic application. Discover more About FAB Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a broad range of age-related diseases. Our novel approach leverages well-known, inherently safe biology with broad potential therapeutic application. Our small molecules promise to be potentia … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … site. --> News 2025 2024 2023 2022 Five Alarm Bio and Proteotype start a major grant-funded collaboration February 2025 Five Alarm Bio ha started a collaborative research project with Proteotype Diagnostics Ltd . to apply Proteotype's PCS proteome characterization technology to tracking how Five Alarm's compounds can reduce cell senescence. The project is funded by a grant from The Babraham Research Campus . See here for more information. Five Alarm Bio presents latest resea … e latest results from our research. Five Alarm Bio is awarded Green Impact Gold Award. July 2024 Five Alarm Bio is proud to have been awarded Gold by the Babraham Research Campus Green Impact scheme for our contribution to sustainable research See here for more details Five Alarm Bio starts collaboration on cognitive decline June 2024 Five Alarm
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Five Alarm Bio and Institute collaborate on research into biology of ageing | Babraham Institute Babraham Institute Research & Facilities Discovery science to improve human health and wellbeing Our Research Healthy Ageing Research Groups Epigenetics Immunology Signalling Open Science Research Integrity Animal Research Annual Research Report Research Features Research Publications Science Facilities Bioinformatics Biological Support Unit Flow Cytometry Gene Targeting Genomics Imaging Mass Spectrometry Enterprise Supporting Industry Engagements Collaborating with Industry Consultancy & F … Five Alarm Bio provides us with an opportunity to take what we have learned and apply that in the development of solutions to medical problems, in this case the potential treatment of ribosomopathies. This research was funded by the UKRI-BBSRC Campus Innovation Award (CIA) via the Babraham Research Campus Collaboration Fund. These awards support a wide range of collaborative engagements across the Babraham Research Campus , aiming to bridge the gap between different disciplin … Five Alarm Bio CEO Dr Janette Thomas. “Our collaborative work with Ian, and the grant that supports it, is just one example of the value of siting Five Alarm Bio on the Babraham Research Campus.” Notes This news article was adapted from a Five Alarm Bio Ltd. press release . Contacts Five Alarm Bio Ltd.: William Baines [email protected] Babraham Institute: Louisa Wood [email protected] About the Babraham Institute The Babraham Institute undertakes world- … , through Institute Strategic Programme Grants and an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities. About Five Alarm Bio Ltd. Five Alarm Bio is a drug discovery company deploying new understanding of the chemical damage associated with aging to discover treatments for serious illness. Our novel approach leverages well-known, inherently safe biology with broad potential th … leverages well-known, inherently safe biology with broad potential therapeutic application. Our small molecules promise to be potential treatments for a range of diseases and disabilities afflicting older people. For more information, please visit www.fivealarmbio.com About Babraham Research Campus Babraham Research Campus Ltd is responsi
Five Alarm Bio - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Inv … Jul 12, 2022 6978758 Series A 8059511 1330478 1468452 6998417 Feb 2022 4352953 Grant (prize money) 6930221 5459552 2499984 Ukri Access funding benchmarks and valuations. Sign up today! View details of Five Alarm Bio 's funding rounds and investors Five Alarm Bio's founders and board of directors Founder? Claim Profile The founders of Five Alarm Bio are Sunil Shah , William Bains and Ann Baker . Here are the details of Five Alarm Bio's key team members: Sunil S
o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science - o2h Ventures Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contact Events news Press releases Blog Media Coverage Documents About Team funds o2h Seven Sisters EIS Growth o2h human health KI EIS o2h human health SEIS o2h human health EIS Portfolio knowledgehub What is Knowledge Intensive EIS fund ? Contact Don’t invest … ocuses on novel approaches to anti-aging with a broad potential for therapeutic application. FAB completed its seed investment round, raising over £500K to further its research to test new compounds. Prior to this, FAB received an Innovate UK grant of £360K in 2022 to initiate and support their research work. Five Alarm Bio (FAB) is developing drug candidates that boost our ability to minimize the effects of aging in humans. Anti-aging science is becoming more relevant than e … ed mechanisms of aging. The investment was made from the ‘o2h Human Health SEIS Fund’ which aims to invest in very early-stage companies covering therapeutic drug opportunities or enabling drug discovery or services. Sunil Shah, CEO of o2h Ventures, said: “We are delighted to have made this investment alongside Meltwind, Cambridge Angels, and Syndicate Room. The combination of the Scientific Depth of our CSO, William Bains, alongside the practical execution skills of the CEO, … investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare. The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in gras … cubating small life science companies. For more information or to invest in the fund, please visit www.o2hventures.com Media Contact: Juhi Shah Marketing Executive [email protected] Connect with us linkedin twitter --> youtube email recent press releases Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-li
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 6 0 obj > endobj 7 0 obj >>> endobj 8 0 obj > stream x��ݎܸ���)�"��(J�b���:�y�$k �/�y ꙱G����JR�m۰�ִ(�O���G7��� �J}}����_�*��O��;|菧�|<>��˧Û�������ηG�b{���ß��w�T�� �x�����͇�蛪=�JLJ?��)|[5��|���CU��� �u������CW��nkj��Bs�xa������.ħo�*ԝ�G_����.u�.���Nm���r�n /�UJ�uM�r��v�@1>^h��sm3j#�� ��jץ�^=VS�����cEz,�z��_��/� �8?��[%x�؞ s�ç;yWŮ�S^���������^��;��ع��8w�G���eй�\�r!$Z�w��l ���G��5��28u(�Qݎ�H/W:X�����?����NM[�1�|� S�q�9i�q�������7�\��T��D�[��/���]�[�;8��D\ػ�P|��vo��6�)^� �.����ء|��n:��y 4��mӞ�� q��s1!@��d��
Episode #7: Dr Janette Thomas - CEO, Five Alarm Bio | Podcast Episode on RSS.com Sign up free Features Resources Pricing Podcasts Sign up free Sign In Cambridge Gravity Encounters Episode #7: Dr Janette Thomas - C... Episode #7: Dr Janette Thomas - CEO, Five Alarm Bio Cambridge Gravity Encounters by Jan Venne, Claudia Smith, Emily James S1 · E8 Dec 8, 2024 48:17 RSS feed Listen on Share About Episode notes Today, we have the pleasure of speaking with Janette Thomas whose journey took a fascinating path from the world of dance to the heart of science. Our guest started her career as a dancer bu
Janette Thomas, Five Alarm Bio | Careers in Discovery Cancel Home Subscribe Profile Careers in Discovery https://feed.podbean.com/careers-in-discovery/feed.xml 15.7K Downloads 211 Episodes Share RSS Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influential figures, the work they are doing, how they got to where they are and what advice they’d give their younger selves. Brought to you by Singular: Building Brilliant Biotechs. Connect with us at: LinkedIn: http
So pleased the Five Alarm Bio Limited team has had success in working towards a more sustainable world. We all strive to make a difference. | Janette Thomas LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Lin … ited 632 followers 11mo Edited Delighted that Five Alarm Bio Limited won a Gold award for our achievements in the Green Impact Scheme at Babraham Research Campus . A fantastic achievement for such a small company team. All thanks to Hannah Mizen for her committment and hard work in galvanising the team to make this happen. The June newsletter noted the scheme had 74 campus users signed up across 11 teams, with a total of 918 sustainability actions completed. https://www.sos-u
5Alarmbio Toggle navigation About FAB Technology News Publications Vacancies Contact Building defences against aging Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a range of age-related diseases, with broad potential therapeutic application. Discover more About FAB Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a broad range of age-related diseases. Our novel approach leverages well-known, inherently safe biology with broad potential therapeutic application. Our small molecules promise to be potentia … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … ide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion. William Bains CSO William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry fr … site. --> News 2025 2024 2023 2022 Five Alarm Bio and Proteotype start a major grant-funded collaboration February 2025 Five Alarm Bio ha started a collaborative research project with Proteotype Diagnostics Ltd . to apply Proteotype's PCS proteome characterization technology to tracking how Five Alarm's compounds can reduce cell senescence. The project is funded by a grant from The Babraham Research Campus . See here for more information. Five Alarm Bio presents latest resea … e latest results from our research. Five Alarm Bio is awarded Green Impact Gold Award. July 2024 Five Alarm Bio is proud to have been awarded Gold by the Babraham Research Campus Green Impact scheme for our contribution to sustainable research See here for more details Five Alarm Bio starts collaboration on cognitive decline June 2024 Five Alarm
5 Alarm Bio Ltd raises £500K in seed round - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ X/Twitter This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Instagram This field is for validation purposes and should be left unchange … d round with support from KPMG Acceleris. Last year, FAB was granted a £360,000 fund from Biomedical Catalyst/Innovate UK to push development of its small molecule inhibitor of extracellular matrix crosslinking, FAB001, as a treatment for chronic wounds. According to CEO Janette Thomas, 5 Alarm Bio was started by three entrepreneurs in 2016. The trio – director Ann Baker, Sunil Shah of o2h ventures, and William Bains, now CSO – did the early research then didnR … – did the early research then didn’t have any funding then got the grant that kickstarted everything. Five Alarm Bio aims to minimise the effects of aging in human fibrotic diseases with a novel small molecule inhibitor that blocks transglutaminase 2 (TG2)-mediated EGGL-crosslinking (?-(?-glutamyl)-lysine) of extracellular matrix proteins. Preclinical research demonstrated that the compound prolonged the life of model organisms by up to 40%. According to the Camb